Re: Abiraterone in metastatic prostate cancer without previous chemotherapy

European Urology

Volumn 63, Issue 5, 2013, Pages 961-

  Di Lorenzo, Giuseppe ^a   Buonerba, Carlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; DOCETAXEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

BONE METASTASIS; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE STUDY; HUMAN; KIDNEY CANCER; NOTE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 84876011600     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.015     Document Type: Note

References (4)

1. P. Rescigno, C. Buonerba, J. Bellmunt, G. Sonpavde, S. De Placido, and G. Di Lorenzo New perspectives in the therapy of castration resistant prostate cancer Curr Drug Targets 13 2012 1676 1686
2. G. Di Lorenzo, and C. Buonerba Kidney cancer: overall survival is an unsuitable primary end point Nat Rev Urol 7 2010 367 368
3. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
4. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 246